Literature DB >> 1457761

Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus.

R Nosadini1, M R Cipollina, A Solini, M Sambataro, A Morocutti, A Doria, P Fioretto, E Brocco, B Muollo, F Frigato.   

Abstract

The aim of this study was to investigate the relationships among insulin resistance and albumin excretion rate in 25 nondiabetic patients with essential hypertension and in 28 patients with non-insulin dependent diabetes mellitus (NIDDM). Two groups of healthy subjects matched for age, sex, and weight served as controls. Patients with essential hypertension were divided into two subgroups: without (H1) and with (H2) microalbuminuria. Diabetic patients were divided into four subgroups: those with normoalbuminuria without (NIDDM1) and with (NIDDM2) hypertension and those with microalbuminuria without (NIDDM3) and with (NIDDM4) hypertension. Whole-body glucose utilization during euglycemic hyperinsulinemic clamp (40 mU/m2/min insulin infusion) was calculated by tracer dilution techniques (6,6 2H2 glucose tracer continuous infusion) and was significantly lower in hypertensives with microalbuminuria than in those without (H2 versus H1 versus controls: 3.41 +/- 0.51 versus 6.52 +/- 0.62 versus 7.03 +/- 0.48 mg/kg/min; mean +/- SE). Whole-body glucose utilization in NIDDM patients--NIDDM4 versus NIDDM3 versus NIDDM2 versus NIDDM1 versus controls--was: 1.86 +/- 0.31 versus 2.21 +/- 0.39 versus 2.01 +/- 0.40 versus 5.98 +/- 0.77 versus 5.52 +/- 0.92 mg/kg/min (mean +/- SE). Whereas the first three subgroups did not differ among themselves, they had significantly lower glucose utilization than did the normotensive NIDDM1 patients without microalbuminuria and nondiabetic controls (P < 0.01). Hypertensives with microalbuminuria had higher Vmax of sodium-lithium countertransport (Na/Li CTT) in red blood cells than did both hypertensives without microalbuminuria and controls. It was also observed that NIDDM patients with microalbuminuria had higher Vmax of Na/Li CTT than did NIDDM patients without microalbuminuria and controls.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457761     DOI: 10.1681/ASN.V34s56

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

1.  Study on the relationship between blood stasis syndrome and clinical pathology in 227 patients with primary glomerular disease.

Authors:  Shen Li; Xiang-rong Rao; Su-xia Wang; Gai-hua Zhang; Xiao-mei Li; Xi-wen Dai; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

2.  A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients.

Authors:  A Pätäri; P Karhapää; H Taipale; U Salmenniemi; E Ruotsalainen; P Vanninen; H Holthöfer; M Laakso
Journal:  Diabetologia       Date:  2005-07-08       Impact factor: 10.122

3.  Subclinical hypothyroidism is independently associated with microalbuminuria in a cohort of prediabetic egyptian adults.

Authors:  Mervat M El-Eshmawy; Hala A Abd El-Hafez; Walaa Othman El Shabrawy; Ibrahim A Abdel Aal
Journal:  Diabetes Metab J       Date:  2013-12-12       Impact factor: 5.376

4.  Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetes.

Authors:  Amy K Mottl; Abigail Lauer; Dana Dabelea; David M Maahs; Ralph B D'Agostino; Larry M Dolan; Lisa K Gilliam; Jean M Lawrence; Beatriz Rodriguez; Santica M Marcovina; Giuseppina Imperatore; Roopa Kanakatti Shankar; Maryam Afkarian; Kristi Reynolds; Angela D Liese; Michael Mauer; Elizabeth J Mayer-Davis
Journal:  Diabetes Care       Date:  2013-07-11       Impact factor: 19.112

5.  Association of Thyroid-Stimulating Hormone Levels with Microvascular Complications in Type 2 Diabetes Patients.

Authors:  Qi Qi; Qiu-Mei Zhang; Chun-Jun Li; Rong-Na Dong; Jin-Jin Li; Jian-Ying Shi; De-Min Yu; Jing-Yun Zhang
Journal:  Med Sci Monit       Date:  2017-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.